Floatz logo

Cyclophosphamide

Amyloidosis

University of Alabama at BirminghamSmall moleculePhase 2Active
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
89/ 100

Competitive context

23 Active assets in the Amyloidosis cohort.

Asset / SponsorPhaseRating
Acoramidis
Bayer
Phase 4BBB
DEXAMETHASONE
Ascentage Pharma Group Inc.
Phase 3BB
Empagliflozin
Columbia University
Phase 4BB
fx-1006a
Pfizer
Phase 4BB
cc-5013
Ascentage Pharma Group Inc.
Phase 3BB

View all 38 →

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →